Top Ten Most Read Articles in 2024

Blood Advances is pleased to announce the following most read articles that were published in 2024.

1. Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population
   Consumption of whole-grain bread, oats, and rice (P < .05), and fruits and vegetables (P = .02) were associated with reduced risk of MGUS.


2. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial
   A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP).


3. BTK inhibitors in CLL: second-generation drugs and beyond
   BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia.


4. Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies
   Chimeric antigen receptor (CAR) T-cell therapies have shown significant benefits in the treatment of hematologic malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoma.  


5. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
   A phase 1 trial assessing safety and efficacy of prophylactic maintenance therapy with venetoclax and azacitidine (Ven/Aza) for patients with high-risk myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) undergoing reduced intensity allogeneic stem cell transplantation (allo-SCT) after Ven and fludarabine/busulfan conditioning (Ven/FluBu2 allo-SCT) with tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis.


6. The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia
   The 2019 American Society of Hematology (ASH) guidelines for immune thrombocytopenia (ITP) included recommendations on the management of adults (recommendations 1-9) and children (recommendations 10-21) with primary ITP.


7. Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study
   Ibrutinib ± rituximab was effective and well tolerated as first-line MCL therapy; outcomes were worse in patients with high-risk disease.


8. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
   The mPRS can accurately segregate 3 groups of patients with AML with different outcomes with HMA and Ven.


9. Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML
   56 out of 79 (84%) patients treated with VEN-combinations for NPM1 molecular failure achieved an MRD response, and 71% became MRD negative.


10. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML
    TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are among the most lethal malignancies, characterized by dismal outcomes with currently available therapies.